Skip to main content
. 2023 Mar 2;10(3):318. doi: 10.3390/bioengineering10030318

Figure 4.

Figure 4

Performance of the IPS in TCGA. (A) The distribution of molecular subtypes and clinicopathological features were compared between low- and high-risk groups. (B) Kaplan–Meier curves of overall survival for patients based on IPS. (C) Gene set enrichment analysis revealed significant oncogenic pathways associated with IPS. IPS, immune prognostic signature; TCGA, The Cancer Genome Atlas; KEGG, Kyoto Encyclopedia of Genes and Genomes. * p < 0.05, ** p < 0.01, *** p < 0.001.